JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 59 filers reported holding JOUNCE THERAPEUTICS INC in Q1 2017. The put-call ratio across all filers is - and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $2,014,000 | – | 91,600 | – | 0.77% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pharmstandard International S.A. | 662,063 | $10,315,000 | 30.07% |
| Omega Fund Management, LLC | 579,650 | $9,031,000 | 5.11% |
| Casdin Capital, LLC | 399,825 | $6,229,000 | 1.76% |
| Cormorant Asset Management, LP | 359,738 | $5,605,000 | 0.99% |
| Foresite Capital Management II, LLC | 119,912 | $1,868,000 | 0.76% |
| Redmile Group, LLC | 955,598 | $14,888,000 | 0.73% |
| PFM Health Sciences, LP | 1,727,997 | $26,922,000 | 0.53% |
| Fosun International Ltd | 285,960 | $4,455,000 | 0.44% |
| Partner Investment Management, L.P. | 14,265 | $222,000 | 0.21% |
| Spark Investment Management LLC | 162,200 | $2,527,000 | 0.14% |